Plasma concentration of micafungin in patients with hematologic malignancies

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Infection and Chemotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S10156-006-0496-1PMID 17334728
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The efficacy of Micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents

  2006cited by this paper
• Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.

  2006cited by this paper
• Proteomic Analysis of Rat Plasma by SELDI-TOF-MS under the Condition of Prevention of Progressive Adriamycin Nephropathy Using Oral Adsorbent AST-120

  2006cited by this paper
• International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

  2005cited by this paper
• Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus.

  2005cited by this paper
• Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

  2004cited by this paper
• A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

  2004cited by this paper
• In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

  2003cited by this paper
• Overview of micafungin (MCFG)

  2002cited by this paper
• In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

  2000cited by this paper

• Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation

  2017cites this paper
• Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.

  2014cites this paper
• Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

  2014cites this paper
• Micafungin for Candida Albicans Pacemaker-Associated Endocarditis: A Case Report and Review of the Literature

  2013cites this paper
• Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation

  2013cites this paper
• Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

  2013cites this paper
• The Eagle-like effect of echinocandins: what’s in a name?

  2013cites this paper
• [A liquid chromatographic method for quantifying unbound micafungin in human plasma and the relationship between the concentrations of unbound and total micafungin in plasma].

  2013cites this paper
• [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].

  2011cites this paper
• Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis

  2011cites this paper
• Direct-injection HPLC method of measuring micafungin in human plasma using a novel hydrophobic/hydrophilic hybrid ODS column.

  2011cites this paper
• [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].

  2009cites this paper
• The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction.

  2009cites this paper
• Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia

  2009cites this paper
• Newer antifungal agents for invasive fungal infections in patients with haematological malignancy

  2009cites this paper
• Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

  2009cites this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008cites this paper
• Pharmacokinetics of new systemic antifungal drugs used in immunocompromised patients

  year unknowncites this paper